Short answer
Neurocrine Biosciences Inc (NBIX) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CMO transition effective September 28, 2026: Eiry W. Roberts succeeds Sanjay Keswani.
Neurocrine Biosciences Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CMO transition effective September 28, 2026: Eiry W. Roberts succeeds Sanjay Keswani
- Keswani’s departure was mutually agreed, with severance eligibility under the Executive Severance Plan
- Roberts’ annual base salary $825,000, with a 2026 target cash bonus equal to 60% of base pay
- Appointment equity package: approximately $625,000 options, $250,000 RSUs, and $375,000 performance RSUs
- Leadership change adds execution risk around clinical development and regulatory strategy during the CMO transition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neurocrine Biosciences Inc 8-K filings
Get the next NBIX 8-K as it lands
Follow NBIX for push alerts, or ask the research agent what this filing means.